Customers coming back on their own: unsolicited repeat business has become the engine
The model's full reasoning — Q3 2018 call → NO1. The user asks to determine if management describes a meaningful share of current business coming from customers returning to buy again without being re-sold, as a real and growing feature of the current business. 2. I need to scan the transcript for any mention of repeat purchases, reorders, renewals, refills, returning patients, or similar concepts. 3. Let's go through the management commentary: - Jim Frates (CFO): Discusses financial results, VIVITROL, ARISTADA, AMPYRA, expenses. No mention of repeat customers or reorders. - Jim Robinson (COO): Discusses VIVITROL growth (unit growth, state initiatives, policy), ARISTADA growth (unit growth, INITIO launch, formulary additions). No mention of repeat customers or reorders. He talks about expanding sales force, new formularies, new prescriptions. - Richard Pops (CEO): Discusses pipeline (5461, 3831, BIIB098, 4230). No mention of repeat customers or reorders. 4. Let's check the Q&A section: - Jason Gerberry asks about 3831 discontinuation rates, BIIB098 switch candidates. No repeat business. - Matthew Holt asks about 4230 subcu dosing, sales force expansion. No repeat business. - Unidentified Analyst asks about 5461 AdCom, new candidates. No repeat business. - Chris Shibutani asks about 5461 data, potential scenarios. No repeat business. - Umer Raffat asks about 5461 RTF, IL-2, injectable buprenorphine. No repeat business. - Paul Matteis asks about 3831 weight gain, 5461. No repeat business. - David Buck asks about VIVITROL 2019, AdCom. No repeat business. - Biren Amin asks about ARISTADA vs SUSTENNA study. No repeat business. - Terence Flynn asks about 5461 commercial prep. No repeat business. - David Risinger asks about VIVITROL acceleration and ICER. No repeat business. 5. Throughout the entire transcript, there is no mention of repeat customers, reorders, renewals, refills, or returning patients as a driver of current business. The growth is described in terms of new prescriptions, new formularies, new states, new sales reps, new products (INITIO), and policy changes. The focus is on acquiring new patients and expanding market access. 6. The question specifically asks if management describes a meaningful share of current activity arriving because people who have already bought once are choosing to come back. There is no such description.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| VIPS | Vipshop Holdings Limited | Q2 2023 | 2023-08-18 | C+ |
| INVH | Invitation Homes Inc. | Q2 2022 | 2022-07-28 | B+ |
| CDXC | ChromaDex Corporation | Q4 2021 | 2022-03-09 | C+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| LRN | Stride, Inc. | Q1 2019 | 2018-10-23 | B |
| TOUR | Tuniu Corporation | Q4 2017 | 2018-03-14 | D |
| ARI | Apollo Commercial Real Estate Finance, I | Q4 2016 | 2017-02-28 | B |
TJX · Q2 2021 → YESThe question is: Does management describe that the company's business is now being driven meaningfully by customers RETURNING TO BUY AGAIN WITHOUT BEING RE-SOLD — existing customers coming back on the...YES The transcript shows management describing existing customers returning and shopping more frequently as a real, observable driver of current results (loyal customers returning and shopping more often, plus rising average ticket and traffic), while treating it as evidence of market-share capture rather than a hope or future initiative. This meets the criteria for a meaningful, 2021-specific repeat behavior. The emphasis on new shoppers and competitor closures is present but does not override the explicit return statement. No contractual lock-in or churn discussion appears. Therefore the answer is YES.
CDXC · Q4 2021 → YESThe question is about whether management describes the business being driven by customers returning to buy again without being re-sold, like existing customers reordering on their own. YES The transcript shows management describing voluntary repeat behavior as a real and strengthening feature of the business. Rob Fried explicitly states: “What we still continue to have is excellent retention. The people who buy Tru Niagen and take Tru Niagen keep taking and buying Tru Niagen. The retention numbers continue to look extremely solid … Amazon has indicated to us that they think we are the — have the highest retention of any dietary supplement that they sell.
LRN · Q1 2019 → YESThe question is about whether management describes that the company's business is now being driven meaningfully by customers RETURNING TO BUY AGAIN WITHOUT BEING RE-SOLD. Existing customers coming bac...YES The transcript shows management explicitly describing reregistration as a meaningful, improving driver of current enrollment growth. Nate Davis states: "the number of families that we registered for another year in a program increased year-over-year. In fact, it was our highest rate of reregistering students in more than seven years of this internal measure." James Rhyu confirms: "we picked up a couple of a few hundred basis points improvement in rereg.